U.S. Markets closed

Interleukin Genetics, Inc. (ILIU)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0069-0.0051 (-42.5000%)
At close: 3:40PM EDT
People also watch

Interleukin Genetics, Inc.

135 Beaver Street
Waltham, MA 02452
United States

Full Time Employees

Key Executives

Mr. Mark B. CarbeauChief Exec. Officer414.41kN/A57
Dr. Kenneth S. Kornman D.D.S., Ph.D.Co-Founder, Pres, Chief Scientific Officer, Sec. and Director405.45kN/A69
Mr. Stephen J. Di Palma M.B.AChief Financial Officer282.63kN/A58
Mr. Stephan ToutainChief Commercial Officer110.54kN/A51
Dr. Lynn Doucette-Stamm Ph.D.VP of Devel. & Clinical OperationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Interleukin Genetics, Inc. develops and markets proprietary genetic tests for chronic diseases and health-related conditions, and for informing lifestyle choices to facilitate wellness. The company primarily offers cardiovascular risk test; and ILUSTRA Inflammation Management Program, which includes the ILUSTRA genetic risk test to identify individuals with a life-long predisposition to over-produce inflammation. It also provides weight management, bone health, heart health, nutritional needs, and wellness select genetic tests under the Inherent Health brand name. The company markets its tests through healthcare professionals, partnerships with health and wellness companies, and other distribution channels, as well as e-commerce Websites. It has clinical research collaborations with Stanford University, the University of North Carolina, the Mayo Clinic, Brigham & Women’s Hospital, University of California, New York University Medical Center, University of Sheffield, Yonsei University Medical Center, Tongji Medical College, University Hospital of Ioannina, and Tuft’s University Medical Center. The company was founded in 1986 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Interleukin Genetics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.